Current Progress in Treating Systemic Lupus Erythematosus Using Exosomes/MicroRNAs.
Yi-Jing LiuHai-Bing MiaoShu LinZhen ChenPublished in: Cell transplantation (2023)
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease associated with impaired organ functions that can seriously affect the daily life of patients. Recent SLE therapies frequently elicit adverse reactions and side effects in patients, and clinical heterogeneity is considerable. Mesenchymal stromal cells (MSCs) have anti-inflammatory, tissue repair, and immunomodulatory properties. Their ability to treat autoimmune diseases largely depends on secreted extracellular vesicles, especially exosomes. The effects of exosomes and microRNAs (miRNAs) on SLE have recently attracted interest. This review summarizes the applications of MSCs derived from bone marrow, adipocyte tissue, umbilical cord, synovial membrane, and gingival tissue, as well as exosomes to treating SLE and the key roles of miRNAs. The efficacy of MSCs infusion in SLE patients with impaired autologous MSCs are reviewed, and the potential of exosomes and their contents as drug delivery vectors for treating SLE and other autoimmune diseases in the future are briefly described.
Keyphrases
- systemic lupus erythematosus
- mesenchymal stem cells
- umbilical cord
- bone marrow
- disease activity
- end stage renal disease
- drug delivery
- stem cells
- cell therapy
- newly diagnosed
- ejection fraction
- chronic kidney disease
- rheumatoid arthritis
- metabolic syndrome
- adipose tissue
- type diabetes
- peritoneal dialysis
- prognostic factors
- current status
- climate change